ResMed (RMD) fundamentals: P/E, valuation, undervalued?
ResMed · Health Care · ref. ETF XLV · price $235.76
In short — ResMed trades at 22.6× earnings (P/E), 17.8× forward, with a net margin of 26.9 % and revenue growth of +9 %. Read: Average P/E (P/E 23 (near the ~20-25 average)).
Is ResMed stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$235.76-14.4% over range
Aug 28, 25low $182.82 · high $283.28Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
22% recommend buying · 9 analysts
Valuation : Average P/E — P/E 23 (near the ~20-25 average)
Valuation
22.6
P/E (price/earnings)
17.8
Forward P/E
9.41
PEG
5.2
Price/book (P/B)
$34.0B
Market cap
10.44
EPS
Profitability & growth
26.9 %
Net margin
+9 %
Revenue growth
+2 %
Earnings growth
$826M
Total debt
ResMed income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2023 | $4.2B | $898M | 21.3 % |
| 2024 | $4.7B | $1.0B | 21.8 % |
| 2025 | $5.1B | $1.4B | 27.2 % |
| 2026 | $5.7B | $1.5B | 26.9 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is ResMed's P/E and is the stock undervalued? What's a good P/E?
ResMed's P/E is 22.6 (forward 17.8). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Average P/E".
Is ResMed profitable?
ResMed has a net margin of 26.9 % (EPS 10.44). The company is profitable.
Is RMD stock expensive?
Our read: "Average P/E" — P/E 23 (near the ~20-25 average). Cross-check with growth and sector.
💬 A question about ResMed? The JPI assistant answers using our backtest data.